Navigation Links
Warner Chilcott Announces Secondary Equity Offering
Date:11/13/2009

180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, by telephone at 1-866-718-1649 or by emailing prospectus@morganstanley.com; Credit Suisse Securities (USA) LLC, at One Madison Avenue, New York, NY 10010, Attention: Credit Suisse Prospectus Department or by telephone at 1-800-221-1037; or J.P. Morgan Securities Inc., at 4 Chase Metrotech Center, Floor 04, Brooklyn, NY 11245-0001, Attention: J.P. Morgan Securities Inc. or by telephone at 1-718-242-8002.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F

Forward Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and unce
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
4. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
5. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
6. Kun Run Biotechnology, Inc. Announces Third Quarter 2009 Results
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Milestone Scientific Announces Third Quarter 2009 Results
9. EF Johnson Technologies Announces Third Quarter Results
10. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
11. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)...  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical company ... technology to deter prescription drug abuse today announced ... Soscia , has been chosen as a ... Health-Care Heroes Awards. The awards are presented annually ... individuals and organizations demonstrating excellence and deserving recognition ...
(Date:5/20/2013)... 2013 Enrollment of patients with Type 2 ... clinical trial of product candidate NewMet ™, a ... Type 2 diabetes. Elcelyx expects to complete enrollment of ... Results of the trial,s primary endpoint of change in ... the read-out for long-term glucose lowering and weight benefits ...
(Date:5/20/2013)... ROCKVILLE, Md. , May 20, 2013  Neuralstem, ... Eva Feldman , MD, PhD, principal investigator, presented ... neural stem cell (NSI-566) trial in the treatment of ... ,s disease) at the neuro diabetes special medical ... Friday. In a talk called "Recent Therapeutic Advances in ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... , PLEASANTON, Calif., Dec. 2 Roche (SIX: RO, ROG; ... Drug Administration (FDA) approved an additional intended use for its ... comprised of up to 96 individual donations. The test, called ... cobas s 201 system, is a qualitative, in-vitro test ...
... , EAST HANOVER, N.J., Dec. ... late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a ... company,s hematology portfolio in advancing the care of patients. ... Hematology (ASH) Annual Meeting and Exposition, highlight the company,s current ...
Cached Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25
(Date:5/20/2013)... Parker Waichman LLP, a national law ... by defective drugs, has filed a lawsuit on behalf ... of the diabetes drug medication Actos (pioglitazone) caused ... 30, 2013, in the U.S. District Court for the ... is one of thousands of cases pending in the ...
(Date:5/20/2013)... 2013 Leading facial plastic surgeon and ENT ... a “Top Doc” in the field of Otolaryngology in the ... The Palm Beacher magazine, one of Palm Beach County’s leading ... the May/June 2013 issue, including 70 of the very best ... events, things to do, health and fitness, people to watch, ...
(Date:5/20/2013)... Mirena IUD lawsuit claims ... recently established in U.S. District Court, Southern District of ... court records, the litigation’s first Status Conference was held ... leadership positions were discussed. So far, at least ... of New York, all of which allege that the ...
(Date:5/20/2013)... 20, 2013 The Environmental ... feature dozens of continuing education credit opportunities for ... Institute of Architects Continuing Education System (AIA/CES), the ... the Interior Design Continuing Education Council (IDCEC). ... 1, 2013 at the Omni Providence Hotel in ...
(Date:5/20/2013)... 2013 Salt Lake Community College’s Know Greater ... Select 25 winners for 2013. As part of the ... Greater Heroes is a leadership training program that involves SLCC ... how to eat right, be active, and avoid drugs and ... Greater Heroes program each year, and visit more than 30 ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:Environmental Design Research Conference to Feature AIA/CES, LA CES, and IDCEC Continuing Education Credits 2Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3
... and binge eating , MONDAY, May 10 (HealthDay News) ... the risk of impulse control disorders, such as problem ... In a new study that included 3,090 patients being ... the United States and Canada, the researchers found that ...
... ... Health Services, Inc. (CV10-2011), asserts that Gentiva, which employs some 30,000 health care workers, treats ... FLSA and refuses to pay these employees for all hours worked. , ... New York, NY (PRWEB) May 10, 2010 -- ...
... . Montreal, May 10, 2010 As fewer people ... among North American youth. A study published in the journal ... Montreal had used waterpipes (also known as shishas or hookahs) in ... due in part to perceptions that they are safer than cigarettes. ...
... Nurse staffing ... newly adopted U.S. Health Care Reform legislation. Current healthcare reform legislation indicates that more ... , ... (PRWEB) May 10, 2010 -- Nurse staffing agency, FlexRN, announces its plans to help agency ...
... treatment even when pulmonary disease looks stable, researchers ... of chronic obstructive pulmonary disease (COPD) leads to increased ... study finds. , British researchers looked at 25,857 COPD ... and 633 ischemic strokes (blockage of blood flow to ...
... from the Georgetown Lombardi Comprehensive Cancer Center at Georgetown ... therapy to "rescue" treatment sensitivity to fulvestrant in estrogen ... on May 15, 2010 as the cover story of ... common second-line therapy for women whose cancer progresses following ...
Cached Medicine News:Health News:Parkinson's Drugs Tied to Compulsive Behaviors 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 2Health News:Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay 3Health News:FlexRN Nurse Staffing Agency Prepares Nurses for Demands of Latest Health Care Reform 2Health News:Researchers discover new way to 'rescue' treatment sensitivity of breast cancer cells 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... is the body's largest and ... inappropriate stresses caused by sports ... excessive strain. Zeuba Vital Knee ... and activates muscles for optimal ...
Comprifix Knee is a comfortable, lightweight, anatomically knitted knee support with an incorporated donut shaped insert for the reduction of pain and swelling....
... Instabilities Lite Lightweight mechanical brace for ... ACL, MCL or LCL instabilities. Unique ... and reduce load on ACL. Does ... Supports the injured or repaired knee ...
Medicine Products: